|
|
|
|
|
|
|
|
CONCLUSION:
Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.